VERICI DX PLC

Investor Presentation • Jan 14, 2022

National Storage Mechanism | Additional information

RNS Number : 4150Y

Verici Dx PLC

14 January 2022

Verici Dx plc

("Verici Dx" or the "Company") 

Investor Presentation

Progress and strategy update

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that CEO Sara Barrington and CFO David Anderson will provide a live progress and strategy update presentation via the Investor Meet Company platform on Tuesday 18 January 2022 at 3:00pm GMT.  This follows the recent update announcement released on 12 January 2022.1

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow Verici Dx plc on the Investor Meet Company platform will automatically be invited.

Notes:

1    https://vericidx.com/progress-and-strategy-update/ 

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Walbrook PR Limited	Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen	Mob: 07980 541 893 / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKXLFFLFLEBBZ